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Abstract
Objectives: To compare the prevalence of unexplained pulmonary artery hypertension (PAH) in
hemodialysis (HD) and peritoneal dialysis (PD) patients and to compare laboratory parameters
between patients with unexplained PAH and those with normal pulmonary artery pressure (PAP).
Methods: We retrospectively reviewed the medical records of 278 chronic HD and 145 chronic PD
patients. Laboratory ﬁndings including hemoglobin, calcium, phosphorus, alkaline phosphatase,
albumin, parathyroid hormone level, serum iron, total iron binding capacity, ferritin, creatinine
and blood urea nitrogen were documented. The results of transthoracic Doppler echocardio-
graphy were used to determine the pulmonary artery pressure (PAP). PAH was deﬁned as a
systolic pulmonary artery pressure (SPAP) ≥35mmHg. To rule out secondary PAH, patients with
cardiac disease, pulmonary disease, collagen vascular disease, volume overload at the time of
echocardiography and positive human immunodeﬁciency virus test were excluded.
Results: Data from 34 patients in group HD and 32 individuals in group PD were analyzed. The
median age of the study population was 57 (45--68) years. The median SPAP value in patients
with PAH was 37.5 (35--45)mmHg. According to the echocardiographic ﬁndings, PAH was found
in 14 (41.1%) patients of HD group and in 6 (18.7%) patients of PD group (P = 0.04). The median
serum iron and hemoglobin was signiﬁcantly lower in patients with PAH compared to those in
patients with normal PAP (P < 0.05).
Conclusion: Unexplained PAH seems to be more frequent in patients undergoing HD than
patients in PD group. Moreover, hemoglobin and serum iron levels are lower in patients with
PAH compared to those in normal PAP group.
© 2010 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L. All rights
reserved.
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Hipertensão pulmonar inexplicável em doentes com diálise peritoneal e hemodiálise
Resumo
Objetivos: Comparar a prevalência de hipertensão arterial pulmonar (PAH) inexplicável em
doentes sob hemodiálise (HD) e diálise peritoneal (PD) e comparar os parâmetros laboratoriais
entre doentes com PAH inexplicável e aqueles com pressão arterial pulmonar normal (PAP).
Métodos: Revimos, de forma retrospetiva, os registos médicos de 278 doentes com HD crónica
e 145 com PD crónica. Dos dados laboratoriais foram registadas hemoglobina, cálcio, fósforo,
fosfatase alcalina, albumina, nível de paratormona, ferro sérico, capacidade total de ligac¸ão
de ferro, ferritina, creatinina e nitrogénio ureico no sangue. Os resultados do ecocardiograma
doppler transtorácico foram utilizados para determinar a pressão arterial pulmonar (PAP). A
PAH foi deﬁnida como uma pressão arterial pulmonar sistólica (SPAP) ≥35mmHg. Para excluir a
PAH secundária, foram excluídos os pacientes com problemas cardíacos, doenc¸as pulmonares,
doenc¸as vasculares do colagénio, excesso de volume na altura do ecocardiograma e vírus de
imunodeﬁciência humana positivo.
Resultados: Foram analisados dados de 34 pacientes no HD e 32 indivíduos no grupo PD. A
mediana de idade da populac¸ão estudada foi de 57 (45--68) anos. O valor médio de SPAP em
doentes com PAH foi de 37,5 (35--45) mmHg. De acordo com os resultados do ecocardiograma,
a PAH foi registada em 14 (41,1%) pacientes do grupo HD e em 6 (18,7%) pacientes do grupo PD
(P = 0,04). A mediana do ferro sérico médio e da hemoglobina estavam signiﬁcativamente mais
baixos em pacientes com PAH em comparac¸ão com os pacientes com PAP normal (P < 0,05).
Conclusão: A PAH inexplicável parece ser mais frequente em pacientes com HD do
que em pacientes no grupo de PD. Além disso, os níveis de hemoglobina e ferro sérico são
inferiores em pacientes com PAH comparando com os do grupo de PAP normal.
© 2010 Sociedade Portuguesa de Pneumologia. Publicado por Elsevier España, S.L. Todos os
direitos reservados.
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Pulmonary arterial hypertension (PAH) is a newly recognized
disease in patients with renal disease.1 In clinical practice,
shunting of blood from the left to the right side of the heart
and increased cardiac output and pulmonary blood ﬂow
are common medical conditions resulting in PAH.2 However,
Yigla et al. ﬁrst noted unexplained PAH in some long-term
hemodialysis (HD) patients during an epidemiologic study.3
They attributed both end stage renal disease (ESRD) and
long-term HD therapy via an arteriovenous (AV) access to
the pathogenesis of PAH in these patients.3,4 On the other
hand, the prevalence of PAH in patients on peritoneal dial-
ysis (PD) is still a matter of debate.5,6 The information in
the literature regarding unexplained or primary PAH in ESRD
patients especially PD patients is limited. Therefore, the aim
of the present study was to compare the prevalence of unex-
plained PAH in HD and PD patients. In addition, we aimed
to compare laboratory parameters between patients with
unexplained PAH and those with normal pulmonary artery
pressure (PAP).
Materials and methods
We retrospectively reviewed the medical records of 278
chronic HD and 145 chronic PD patients treated at the hos-
pitals afﬁliated to the university in Tabriz, Iran between
May 2008 and January 2010. The patients’ data including
age, sex, co-morbidities, medications, tobacco use, etiol-
ogy of renal failure, vascular access type, and duration of
i
t
w
wialysis therapy were recorded. Laboratory ﬁndings includ-
ng hemoglobin, calcium, phosphorus, alkaline phosphatase,
lbumin, parathyroid hormone (PTH) level, serum iron, total
ron binding capacity, ferritin, creatinine and blood urea
itrogen were documented. The results of transthoracic
oppler echocardiography were used to determine the pul-
onary artery pressure, expiratory and inspiratory inferior
ena cava (IVC) diameters and percent collapse, left ventric-
lar ejection fraction, presence of valvular diseases, etc.
AH was deﬁned as a systolic pulmonary artery pressure
SPAP) ≥35mmHg.
Patients with cardiac disease, pulmonary disease, col-
agen vascular disease, volume overload at the time
f echocardiography (<50% collapsibility in IVC diame-
er) and positive human immunodeﬁciency virus (HIV) test
ere excluded. Additionally, patients treated with dialysis
3 months or >7 years were not included in the present study.
Data were presented as median (interquartile range). All
tatistical analyses were performed with Statistical Package
f Social Science (SPSS Inc., Chicago, IL) for Windows version
6. The Mann--Whitney U test, chi-square test and Fisher’s
xact test were used wherever appropriate. A P-value <0.05
as considered statistically signiﬁcant.
esults
ata from 66 patients were analyzed: 34 in group HD and 32
n group PD (Fig. 1). The median age of the study popula-
ion was 57 (45--68) years. The median duration of dialysis
as 102 (54.25--161) weeks in HD group and 44 (24.5--82)
eeks in PD group (P = 0.001, Mann--Whitney U test). Among
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423 patients on
dialysis
86 patients in HD
group 
292 patients excluded due
to incomplete medical
profiles
131 patients
enrolled 
45 patients in PD
group 
52 patients excluded: 
11 cardiac diseases
8 pulmonary diseases 
1 collagen vascular disease 
7 volume overload 
1 HIV-positive 
   11 no PAP measurement in 
echocardiography
   8 not in the range of dialysis
duration 
5 others 
13 patients excluded: 
5 cardiac diseases
2 pulmonary diseases
2 volume overload 
   4 no PAP measurement in 
echocardiography
34 patients in HD
group
32 patients in PD
group
Study
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D group, 18 patients (53%) had proximal and 16 patients
47%) had distal arteriovenous ﬁstula (AVF). However, none
f the patients in PD group had functional AVF; 28 patients
ere primarily in PD group and 4 patients had primary non-
unctional AVF.
The median SPAP value in patients with PAH was 37.5
35--45)mmHg. According to the echocardiographic ﬁndings,
AH was detected in 20 (30.3%) patients: 14 (41.1%) patients
n HD group and 6 (18.7%) patients in PD group (P = 0.04,
isher’s exact test). Among HD patients with PAH, vascular
ccess type was proximal and distal AVF in 8 (57.1%) and 6
42.9%) patients, respectively. None of the PD patients with
AH had vascular access. There were no differences in gen-
er, age, weight, duration of dialysis, calcium, phosphorus,
lkaline phosphatase, albumin, parathyroid hormone level,
otal iron binding capacity, ferritin, creatinine and blood
rea nitrogen between the patients with PAH and those with
ormal PAP (Table 1, P > 0.05). The median serum iron was
igniﬁcantly lower in patients with PAH (47g/dL) compared
o that in patients with normal PAP (71.5g/dL, P = 0.001,
able 1). The median hemoglobin of patients with normal
AP was not comparable to that of PAH patients (11.3mg/dL
s. 9.9mg/dL, P = 0.004, Table 1).
iscussion
he present study revealed that PAH was more frequent in
atients undergoing HD (41.1%) than in patients of PD group
18.7%). Previous studies have mostly reported the preva-
ence of PAH in HD patients, but not in PD patients. Amin
t al.,7 Yigla et al.4 and Tarrass et al.8 concluded that there
as a high prevalence of PAH among patients with ESRD
eceiving long-term HD with surgical AV access. The two lat-
er studies differed with regard to the type of PAH; primary
w
u
r
lﬂowchart.
nd secondary PAH in the former and primary PAH in the
atter. Nakhoul and colleagues9 and Havlucu et al.10 found
AH in approximately half of the HD patients. Nakhoul et al.
oted a signiﬁcant decrease in PAP following successful kid-
ey transplants and temporary closure of AV access in some
AH patients.9 Kumbar et al. detected PAH (primary and sec-
ndary) in 42% of patients on PD.5 In a recent study on HD
nd PD patients, Bozbas and co-workers found a higher PAH
atio in HD compared to that in the PD group (18.8% vs.
.9%). Patients with secondary PAH were not excluded in
heir study.6 Furthermore, the duration of dialysis in the HD
roup was longer than that in the PD group. This may account
or the differing incidence of PAH between the two groups.
owever, previous studies have highlighted no difference in
he duration of HD therapy between patients with PAH and
hose without PAH.7,11
In recent studies numerous parameters have been com-
ared between patients with PAH and those with normal
AP. In a study on HD patients, Abassi et al.12 and Yigla
t al.4 found that those with elevated PAP had signiﬁ-
antly lower hemoglobin and hematocrit levels. Similarly,
e observed signiﬁcantly lower hemoglobin levels in PAH
atients in the present study. In contrast, other researchers
ave failed to detect any difference in hemoglobin and
ematocrit levels between the two groups.5,6,9,10 In addi-
ion, we found lower serum iron levels in patients with PAH
ompared to those in normal PAP group. This ﬁnding has not
een previously reported in patients undergoing HD and/or
D. In a recent study, Ruiter et al. interestingly revealed
hat iron deﬁciency was common in idiopathic PAH.13 The
resent study’s ﬁndings are consistent with previous studies
hich found that PTH level and calcium--phosphorus prod-
ct did not differ.4,5,7,9,12 However, Havlucu and colleagues
eported higher calcium--phosphorus production and PTH
evels in patients with PAH.10 Although we failed to ﬁnd a
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Table 1 Patients’ demographic data and laboratory parameters (n = number of patients).
Normal PAP (n = 46) Elevated PAP (n = 20) P value
Gender (male:female) 22:24 8:12 0.79
Age (years) 53.5 (39.75--68.5) 65 (53.75--67.75) 0.14
Weight (kg) 66.5 (54--75) 60.5 (53.25--69.5) 0.21
Duration of dialysis (weeks) 57 (27.75--140) 77 (44.5--171) 0.32
Hemoglobin (mg/dL) 11.3 (9.95--12.05) 9.9 (9.5--10.5) 0.004*
Calcium (Ca) (mg/dL) 8.8 (8.17--9.2) 8.35 (7.82--9) 0.20
Phosphorus (P) (mg/dL) 5.45 (4.37--6.7) 6.11 (4.57--7.4) 0.25
Ca.P product 46.2 (39.35--56.22) 52.13 (38.2--61.37) 0.45
Alkaline phosphatase (IU/L) 249 (193.75--297) 215 (174--312.5) 0.72
Albumin (g/dL) 4.1 (3.6--4.3) 3.8 (3.62--4.2) 0.24
Parathyroid hormone (pg/mL) 197 (71--412) 213 (172--509) 0.32
Serum iron (SI) (g/dL) 71.5 (58.5--98.25) 47 (31.5--63) 0.001*
TIBC (g/dL) 291.5 (240.75--333) 295 (231.5--329.5) 0.98
SI/TIBC 0.25 (0.19--0.32) 0.16 (0.14--0.21) 0.002*
Ferritin (ng/mL) 305 (148--682) 410 (223.9--721) 0.26
Creatinine (mg/dL) 7.75 (5.05--9.85) 7.6 (6.57--9.07) 0.77
BUN (mg/dL) 56 (45.12--77.37) 70.5 (55.5--84.62) 0.09
PAP, pulmonary artery pressure; TIBC, total iron binding capacity; BUN, blood urea nitrogen.
*
w
a
o
h
t
r
o
m
p
I
w
e
t
s
s
q
g
h
P
i
P
i
C
T
RStatistically signiﬁcant (P < 0.05).
signiﬁcant difference in ferritin levels between PAH and nor-
mal PAP groups, Kumbar et al. disclosed lower ferritin levels
in patients with PAH.5
There is not yet a clear explanation for the high preva-
lence of PAH in ESRD. In HD patients, numerous hormonal
and metabolic disorders have been attributed to vaso-
constriction of pulmonary vessels and pulmonary artery
calciﬁcation.10,12,14 However, Amin et al.7 and Yigla et al.15
did not conﬁrm the role of secondary hyperparathyroidism
and pulmonary calciﬁcation as the etiology of PAH in
ESRD patients. Later, Nakhoul et al. studied the role of
two endothelial-derived molecules, endothelin-1 and nitric
oxide (NO), in the pathogenesis of PAH in HD patients via AV
access.9 Although impaired NO production and reduced sen-
sitivity to NO have already been described in patients with
chronic renal failure,16 Nakhoul et al. ﬁrst demonstrated
a link between impaired NO production and PAH in ure-
mic patients receiving chronic HD therapy via AV access.9
This ﬁnding may be also generalized to the patients on PD
therapy; NO deﬁciency has been described in PD patients.17
Along with high cardiac output resulting from the AV access,
such an endothelial dysfunction may reduce the capability
of the pulmonary vasculature to maintain the raised cardiac
output and may subsequently contribute to the development
of PAH in ESRD patients.9,18 An increase in the cardiac out-
put and pulmonary blood ﬂow due to the AV access may
change shear stress.9 This may alter endothelial function
or release of mediators through induction of gene expres-
sion patterns.19 Moreover, a venous torrent of microbubbles
stemming from tubing or dialyzer has been proposed as a
potential etiological factor in the development of PAH in
this population. These microbubbles obstruct capillaries in
the lungs, which may cause tissue ischemia, an inﬂammatory
response and complement activation.20
This study has certain limitations. The retrospective
observational design of the study might be considered aeakness in this work. Moreover, PAP was measured by
non-invasive method, Doppler echocardiography, with-
ut obtaining direct invasive measurements (e.g. right
eart catheterization). However, measurements of PAP by
he applied Doppler echocardiographic method have been
eported to have a good correlation with measurements
btained by invasive methods in some studies.7,21,22 This
ethod of PAP measurement has been widely applied in
revious studies on PAH in patients on HD or PD.1,4--11,15
n addition, doses of erythropoiesis-stimulating agent (ESA)
ere not available in either group. Higher doses of ESA in
ither group might be a confounding factor and interesting
o observe. Furthermore, the effect of the duration of dialy-
is on the incidence of PAH was not addressed in the present
tudy.
In conclusion, unexplained PAH seems to be more fre-
uent in patients undergoing HD than patients in the PD
roup. Moreover, among numerous laboratory parameters,
emoglobin and serum iron levels are lower in patients with
AH compared to those in normal PAP group. Due to the high
mportance of PAH in ESRD patients receiving both HD and
D therapy, the present ﬁndings need to be further explored
n larger studies.
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